---
title: "Ibrance (palbociclib) in HR-positive HER2-negative advanced or metastatic breast cancer: Safety questions"
description: "Safety questions on Ibrance (palbociclib) in HR-positive HER2-negative advanced or metastatic breast cancer, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Side effects, Warnings, and Safety management. Questions: What are the most common side effects of Ibrance with letrozole (PALOMA-2)? What are the most common side effects of Ibrance with fulvestrant (PALOMA-3)? What blood test abnormalities occur with Ibrance (PALOMA-2 and PALOMA-3)? Does Ibrance cause nosebleeds, dry eye, or blurred vision? 5 further questions follow. 9 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/ibrance--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/safety"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Ibrance (palbociclib) in HR-positive HER2-negative advanced or metastatic breast cancer: Safety questions

Manufacturer: Pfizer Laboratories Div Pfizer Inc  
Prescribing information: [Ibrance](https://labeling.pfizer.com/ShowLabeling.aspx?id=12921), [Ibrance](https://labeling.pfizer.com/ShowLabeling.aspx?id=2191)

Safety questions that apply to every indication of Ibrance are on [Ibrance (palbociclib), all indications: Safety](https://www.evicenter.com/medical-information/ibrance/safety).

## Side effects

<a id="ibrance-side-effects-letrozole"></a>

### What are the most common side effects of Ibrance with letrozole (PALOMA-2)?

Applies to: PALOMA-2: postmenopausal women with ER-positive, HER2-negative advanced breast cancer and no prior systemic treatment for advanced disease (IBRANCE plus letrozole vs placebo plus letrozole)

> “The most common adverse reactions (≥10%) of any grade reported in PALOMA-2 for IBRANCE plus letrozole vs placebo plus letrozole were neutropenia (80% vs 6%), infections (60% vs 42%), leukopenia (39% vs 2%), fatigue (37% vs 28%), nausea (35% vs 26%), alopecia (33% vs 16%), stomatitis (30% vs 14%), diarrhea (26% vs 19%), anemia (24% vs 9%), rash (18% vs 12%), asthenia (17% vs 12%), thrombocytopenia (16% vs 1%), vomiting (16% vs 17%), decreased appetite (15% vs 9%), dry skin (12% vs 6%), pyrexia (12% vs 9%), and dysgeusia (10% vs 5%).”

Source: [IBRANCE: PALOMA-2 Efficacy & Safety, captured 2026-11-13](https://ibrance.pfizerpro.com/af/paloma-2/efficacy-safety#:~:text=The%20most%20common%20adverse%20reactions,and%20dysgeusia%20%2810%25%20vs%205%25%29.)

> “The most frequently reported Grade ≥3 adverse reactions (≥5%) in PALOMA-2 for IBRANCE plus letrozole vs placebo plus letrozole were neutropenia (66% vs 2%), leukopenia (25% vs 0%), infections (7% vs 3%), and anemia (5% vs 2%).”

Source: [IBRANCE: PALOMA-2 Efficacy & Safety, captured 2026-11-13](https://ibrance.pfizerpro.com/af/paloma-2/efficacy-safety#:~:text=The%20most%20frequently%20reported%20Grade,and%20anemia%20%285%25%20vs%202%25%29.)

<a id="ibrance-side-effects-fulvestrant"></a>

### What are the most common side effects of Ibrance with fulvestrant (PALOMA-3)?

Applies to: PALOMA-3: women with HR-positive, HER2-negative advanced breast cancer whose disease progressed on or after prior endocrine therapy (IBRANCE plus fulvestrant vs placebo plus fulvestrant)

> “The most common adverse reactions (≥10%) of any grade reported in PALOMA-3 for IBRANCE plus fulvestrant vs placebo plus fulvestrant were neutropenia (83% vs 4%), leukopenia (53% vs 5%), infections (47% vs 31%), fatigue (41% vs 29%), nausea (34% vs 28%), anemia (30% vs 13%), stomatitis (28% vs 13%), diarrhea (24% vs 19%), thrombocytopenia (23% vs 0%), vomiting (19% vs 15%), alopecia (18% vs 6%), rash (17% vs 6%), decreased appetite (16% vs 8%), and pyrexia (13% vs 5%).”

Source: [IBRANCE: PALOMA-3 Efficacy & Safety Data, captured 2026-11-13](https://ibrance.pfizerpro.com/af/paloma-3/efficacy-safety#:~:text=%2843%25%20vs%2030%25%29.-,The%20most%20common%20adverse%20reactions%20%28%E2%89%A510%25%29%20of%20any%20grade%20reported,and%20pyrexia%20%2813%25%20vs%205%25%29.)

> “The most frequently reported Grade ≥3 adverse reactions (≥5%) in PALOMA-3 for IBRANCE plus fulvestrant vs placebo plus fulvestrant were neutropenia (66% vs 1%) and leukopenia (31% vs 2%).”

Source: [IBRANCE: PALOMA-3 Efficacy & Safety Data, captured 2026-11-13](https://ibrance.pfizerpro.com/af/paloma-3/efficacy-safety#:~:text=%2813%25%20vs%205%25%29.-,The%20most%20frequently%20reported%20Grade%20%E2%89%A53%20adverse%20reactions%20%28%E2%89%A55%25%29%20in,and%20leukopenia%20%2831%25%20vs%202%25%29.)

<a id="ibrance-lab-abnormalities"></a>

### What blood test abnormalities occur with Ibrance (PALOMA-2 and PALOMA-3)?

> “Lab abnormalities occurring in PALOMA-2 (all grades, IBRANCE + letrozole vs placebo + letrozole) were decreased white blood cells (97% vs 25%), increased blood creatinine (96% vs 91%), decreased neutrophils (95% vs 20%), decreased hemoglobin (78% vs 42%), decreased platelets (63% vs 14%), increased aspartate aminotransferase (52% vs 34%), and increased alanine aminotransferase (43% vs 30%)<sup>1,2</sup>”

Source: [IBRANCE: PALOMA-2 Efficacy & Safety, captured 2026-11-13](https://ibrance.pfizerpro.com/af/paloma-2/efficacy-safety#:~:text=Lab%20abnormalities%20occurring%20in%20PALOMA%2D2,increased%20alanine%20aminotransferase%20%2843%25%20vs)

> “Lab abnormalities occurring in PALOMA-3 (all grades, IBRANCE + fulvestrant vs placebo + fulvestrant) were decreased white blood cells (99% vs 26%), decreased neutrophils (96% vs 14%), increased blood creatinine (95% vs 82%), decreased hemoglobin (78% vs 40%), decreased platelets (62% vs 10%), increased aspartate aminotransferase (43% vs 48%), and increased alanine aminotransferase (36% vs 34%)<sup>1,2</sup>”

Source: [IBRANCE: PALOMA-3 Efficacy & Safety Data, captured 2026-11-13](https://ibrance.pfizerpro.com/af/paloma-3/efficacy-safety#:~:text=Lab%20abnormalities%20occurring%20in%20PALOMA%2D3,increased%20alanine%20aminotransferase%20%2836%25%20vs)

<a id="ibrance-nosebleeds-dry-eye"></a>

### Does Ibrance cause nosebleeds, dry eye, or blurred vision?

> “Clinically relevant adverse reactions in <10% of patients who received IBRANCE plus letrozole in PALOMA-2 included epistaxis (9%), lacrimation increased (6%), dry eye (4.1%), vision blurred (3.6%), and febrile neutropenia (2.5%).”

Source: [IBRANCE: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=12921#:~:text=Clinically%20relevant%20adverse%20reactions%20in,%283.6%25%29%2C%20and%20febrile%20neutropenia%20%282.5%25%29.)

> “Clinically relevant adverse reactions in <10% of patients who received IBRANCE plus fulvestrant in PALOMA-3 included asthenia (8%), dysgeusia (7%), epistaxis (7%), lacrimation increased (6%), dry skin (6%), vision blurred (6%), dry eye (3.8%), and febrile neutropenia (0.9%).”

Source: [IBRANCE: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=12921#:~:text=Clinically%20relevant%20adverse%20reactions%20in%20%3C10%25%20of%20patients%20who%20received%20IBRANCE%20plus,-fulvestrant%20in%20PALOMA%2D3)

<a id="ibrance-stopping-for-side-effects"></a>

### How often did side effects lead to stopping Ibrance (PALOMA-2, PALOMA-3)?

> “Dose reductions due to an adverse reaction of any grade occurred in 36% of patients receiving IBRANCE plus letrozole. No dose reduction was allowed for letrozole in PALOMA-2.
>
> Permanent discontinuation associated with an adverse reaction occurred in 43 of 444 (10%) patients receiving IBRANCE plus letrozole and in 13 of 222 (6%) patients receiving placebo plus letrozole. Adverse reactions leading to permanent discontinuation for patients receiving IBRANCE plus letrozole included neutropenia (1.1%) and alanine aminotransferase increase (0.7%).”

Source: [IBRANCE: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=12921#:~:text=Dose%20reductions%20due%20to%20an,and%20alanine%20aminotransferase%20increase%20%280.7%25%29.)

> “Dose reductions due to an adverse reaction of any grade occurred in 36% of patients receiving IBRANCE plus fulvestrant. No dose reduction was allowed for fulvestrant in PALOMA-3.
>
> Permanent discontinuation associated with an adverse reaction occurred in 19 of 345 (6%) patients receiving IBRANCE plus fulvestrant, and in 6 of 172 (3%) patients receiving placebo plus fulvestrant. Adverse reactions leading to discontinuation for those patients receiving IBRANCE plus fulvestrant included fatigue (0.6%), infections (0.6%), and thrombocytopenia (0.6%).”

Source: [IBRANCE: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=12921#:~:text=was%204.8%20months.-,Dose%20reductions%20due%20to%20an%20adverse%20reaction%20of%20any%20grade,infections%20%280.6%25%29%2C%20and%20thrombocytopenia%20%280.6%25%29.)

## Warnings

<a id="ibrance-neutropenia"></a>

### How common is neutropenia (low neutrophil count) with Ibrance?

> “Neutropenia was the most frequently reported adverse reaction in PALOMA-2 with an incidence of 80% and PALOMA-3 with an incidence of 83%. A Grade ≥3 decrease in neutrophil counts was reported in 66% of patients receiving IBRANCE plus letrozole in PALOMA-2 and 66% of patients receiving IBRANCE plus fulvestrant in PALOMA-3. In PALOMA-2 and PALOMA-3, the median time to first episode of any grade neutropenia was 15 days and the median duration of Grade ≥3 neutropenia was 7 days [see Adverse Reactions (6.1)].”

Source: [IBRANCE: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=12921#:~:text=Neutropenia%20was%20the%20most%20frequently,days%20%5Bsee%20Adverse%20Reactions%20%286.1%29%5D.)

> “Febrile neutropenia has been reported in 1.8% of patients exposed to IBRANCE across PALOMA-2 and PALOMA-3. One death due to neutropenic sepsis was observed in PALOMA-3.”

Source: [IBRANCE: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=12921#:~:text=Febrile%20neutropenia%20has%20been%20reported,sepsis%20was%20observed%20in%20PALOMA%2D3.)

<a id="ibrance-lung-problems"></a>

### Can Ibrance cause lung problems (ILD or pneumonitis)?

> “Severe, life-threatening, or fatal interstitial lung disease (ILD) and/or pneumonitis can occur in patients treated with CDK4/6 inhibitors, including IBRANCE when taken in combination with endocrine therapy”

Source: [IBRANCE: PALOMA-2 Efficacy & Safety, captured 2026-11-13](https://ibrance.pfizerpro.com/af/paloma-2/efficacy-safety#:~:text=Severe%2C%20life%2Dthreatening%2C%20or%20fatal%20interstitial,in%20combination%20with%20endocrine%20therapy)

> “Across clinical trials (PALOMA-1, PALOMA-2, PALOMA-3):
> 1% of IBRANCE-treated patients had ILD/pneumonitis of any grade
> 0.1% had Grade 3 or 4
> No fatal cases were reported
> Additional cases of ILD/pneumonitis have been observed in the post-marketing setting, with fatalities reported”

Source: [IBRANCE: PALOMA-2 Efficacy & Safety, captured 2026-11-13](https://ibrance.pfizerpro.com/af/paloma-2/efficacy-safety#:~:text=Across%20clinical%20trials%20%28PALOMA%2D1%2C%20PALOMA%2D2%2C,post%2Dmarketing%20setting%2C%20with%20fatalities%20reported)

> “Monitor patients for pulmonary symptoms indicative of ILD/pneumonitis (e.g., hypoxia, cough, dyspnea)
> In patients who have new or worsening respiratory symptoms and are suspected to have developed pneumonitis, interrupt IBRANCE immediately and evaluate the patient
> Permanently discontinue IBRANCE in patients with severe ILD or pneumonitis”

Source: [IBRANCE: PALOMA-2 Efficacy & Safety, captured 2026-11-13](https://ibrance.pfizerpro.com/af/paloma-2/efficacy-safety#:~:text=Monitor%20patients%20for%20pulmonary%20symptoms,with%20severe%20ILD%20or%20pneumonitis)

## Safety management

<a id="ibrance-neutropenia-dose-changes"></a>

### How often did neutropenia lead to Ibrance dose changes (PALOMA-2, PALOMA-3)?

> “Dose reductions or dose modifications due to neutropenia occurred in 24.3% of patients taking IBRANCE + letrozole in PALOMA-2<sup>3</sup>”

Source: [IBRANCE: PALOMA-2 Efficacy & Safety, captured 2026-11-13](https://ibrance.pfizerpro.com/af/paloma-2/efficacy-safety#:~:text=Dose%20reductions%20or%20dose%20modifications,taking%20IBRANCE%20%2B%20letrozole%20in)

> “1.1% of patients discontinued IBRANCE due to neutropenia in PALOMA-2<sup>1,2</sup>”

Source: [IBRANCE: PALOMA-2 Efficacy & Safety, captured 2026-11-13](https://ibrance.pfizerpro.com/af/paloma-2/efficacy-safety#:~:text=1.1%25%20of%20patients%20discontinued%20IBRANCE%20due%20to%20neutropenia%20in)

> “Dose reductions or dose modifications due to neutropenia occurred in 21.2% of patients taking IBRANCE + fulvestrant in PALOMA-3<sup>3</sup>”

Source: [IBRANCE: PALOMA-3 Efficacy & Safety Data, captured 2026-11-13](https://ibrance.pfizerpro.com/af/paloma-3/efficacy-safety#:~:text=Dose%20reductions%20or%20dose%20modifications,taking%20IBRANCE%20%2B%20fulvestrant%20in)

> “No patients discontinued IBRANCE due to neutropenia in PALOMA-3<sup>1,2</sup>”

Source: [IBRANCE: PALOMA-3 Efficacy & Safety Data, captured 2026-11-13](https://ibrance.pfizerpro.com/af/paloma-3/efficacy-safety#:~:text=No%20patients%20discontinued%20IBRANCE%20due%20to%20neutropenia%20in)

<a id="ibrance-g-csf"></a>

### Was G-CSF allowed for neutropenia in the Ibrance PALOMA-2 and PALOMA-3 trials?

> “Primary prophylactic use of granulocyte-colony stimulating factors was not permitted in PALOMA-2, but they could be used to treat treatment-emergent neutropenia as indicated by the current American Society of Clinical Oncology guidelines<sup>3</sup>”

Source: [IBRANCE: PALOMA-2 Efficacy & Safety, captured 2026-11-13](https://ibrance.pfizerpro.com/af/paloma-2/efficacy-safety#:~:text=Primary%20prophylactic%20use%20of%20granulocyte%2Dcolony,American%20Society%20of%20Clinical%20Oncology)

> “Primary prophylactic use of granulocyte-colony stimulating factors (GCSFs) was not permitted in PALOMA-3, but they could be used to treat treatment-emergent neutropenia as indicated by the current American Society of Clinical Oncology guidelines<sup>3</sup>”

Source: [IBRANCE: PALOMA-3 Efficacy & Safety Data, captured 2026-11-13](https://ibrance.pfizerpro.com/af/paloma-3/efficacy-safety#:~:text=Primary%20prophylactic%20use%20of%20granulocyte%2Dcolony,American%20Society%20of%20Clinical%20Oncology)

## Related pages
- [Medical information: Ibrance (palbociclib): HR-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/medical-information/ibrance--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer)
- [Indication](https://www.evicenter.com/medical-information/ibrance--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/ibrance--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-trials)
- [Specific populations](https://www.evicenter.com/medical-information/ibrance--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/ibrance--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/dosing-and-administration)
